Ketamine could offer lasting light at the end of depression tunnel, new study shows

17 March 2016

The latest research on ketamine as a treatment for depression suggests that it could provide real hope for sufferers.

Ketamine infusion therapy has faced widespread resistance due to fears over addiction risks, benefits being only short-lived and the lack of large-scale studies on its safety and efficacy.

A new study, led by Theodore Henderson, a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, USA, appears to allay these fears and contrasts with warnings put out by the American Psychiatric Association.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK